European Psychiatry
August 27, 2024
J. Garde Gonzalez, A. Oliva Lozano, P. Herrero Ortega et al.
Introduction Visual hallucinations are a relatively common neurological complaint. Peduncular hallucinosis (PH) stands out as a distinct entity, characterized by complex visual hallucinations resulting from structural lesions in the brainstem or diencephalon. Objectives We aim to provide an overview of the clinical features, etiological factors, and management strategies associated with PH,...
European Psychiatry
August 27, 2024
Aysegul Yay-Pence, Merve Coldur, Zumra Atalay et al.
Introduction Medical students face an enormous amount of stress (Dyrbye LN et al. Ann Intern Med 2008; 149: 334-41). They suffer from higher rates of depression, anxiety, and suicide compared to the general population. Despite experiencing more mental health problems, there is a lack of research exploring ways to improve their mental health. Although there are a few small sample studies...
European Psychiatry
April 1, 2024
K. P. Kuypers
3 citations
Abstract Microdosing psychedelics has garnered considerable attention within both nonprofessional circles and the scientific community in recent years. This method involves taking small, non-hallucinogenic doses of substances like LSD or psilocybin over weeks or months, purportedly to enhance specific behaviors, emotions, or address psychiatric conditions. Exploring these assertions is crucial...
European Psychiatry
April 1, 2024
Shannon Dames, Crosbie Watler, P. Kryskow et al.
1 citation
Introduction This review explores the benefits of incorporating personal experience(s) with non-ordinary states of consciousness as a core component of Psychedelic-Assisted Therapy (PaT) training.The program incorporates an optional experiential training component. We collaborate with professionals affiliated with a Canadian non-profit organization specializing in PaT experiential training. As...
European Psychiatry
April 1, 2024
N. Kabir, B. Anderson, Lisa Bouchet et al.
1 citation
Introduction Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, LSD, MDMA and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress and post-traumatic stress disorder. Objectives...
European Psychiatry
April 1, 2024
Venessa Tsang, C. Roney
1 citation
Introduction Psilocybin-assisted therapy (PAT) has demonstrated significant potential in alleviating anxiety, depression, and psychological distress among individuals with terminal illnesses. However, numerous barriers prevent equitable access to this transformative treatment. Objectives This study seeks to gather the perspectives of patients on the waitlist of PAT. Methods Semi-structured...
European Psychiatry
April 1, 2024
V. Tsang
IntroductionThe study aimed to evaluate the effectiveness of a device called “Apollo” in reducing anxiety, as compared to a control group. Participants were divided into two groups: the intervention group (receiving the “Apollo” device) and the control group (receiving no intervention).ObjectivesThe primary outcome measure was the change in Generalized Anxiety Disorder 7-item (GAD-7) scores,...
European Psychiatry
April 1, 2024
Christine Zu Eulenburg, Evangelos Papanastasiou, Karin Schmid et al.
IntroductionCurrent ketamine-based therapies for treatment-resistant depression (TRD) often induce dissociative effects. A novel oral PR ketamine formulation (KET01) results in a low and delayed peak concentration of ketamine, high hydroxynorketamine concentration, and is associated with limited dissociative properties.ObjectivesTo investigate efficacy, safety, and pharmacokinetics of KET01 in...
European Psychiatry
April 1, 2024
J. S. Seo
Introduction Recently, the pros and cons have been debating in Korea even before the approval of use of medical marijuana with very strict limitations. And the next controversial topic is psychedelics. In 1890, when mescaline was first isolated from peyote cactus, clinical researches began, but due to its harmful effects, it was thereafter legally prohibited in 1970 in USA. However, a...
European Psychiatry
April 1, 2024
Arun K. Iyer, W. Upadhyaya
Introduction Research into dreams, have shown the association between increased frequency of distressing dreams, specific content themes (analysed using the Hall Van de Castle system) and greater incidence of progression of neurological conditions and dementia. The history of predicting illnesses by the content of dreams, in the western world is popularly traced backed to the ancient Greek...
European Psychiatry
April 1, 2024
J. H. Shepherd, Angela Hickman, Caitlin Baten et al.
Introduction There has been rapidly growing interest in understanding the pharmaceutical and clinical properties of psychedelic and dissociative drugs, with a particular focus on ketamine. This compound, long known for its anesthetic and dissociative properties, has garnered attention due to its potential to rapidly alleviate symptoms of depression, especially in individuals with...
European Psychiatry
April 1, 2024
Amanda M. Klassen, Caitlin Baten, J. H. Shepherd et al.
Introduction Major depressive disorder (MDD) is a tremendous global disease burden and the leading cause of disability worldwide. Unfortunately, individuals diagnosed with MDD typically experience a delayed response to traditional antidepressants and many do not adequately respond to pharmacotherapy, even after multiple trials. The critical need for novel antidepressant treatments has led to a...
European Psychiatry
April 1, 2024
V. Tsang
Introduction While much is known about psilocybin-assisted therapy for individuals, little is known about the experience of participants in a group psilocybin therapy model. Objectives In an attempt to bridge this gap in the literature, a program development and quality improvement effort was launched. Methods Thirty-one psychedelic-assisted therapy (PaT) sessions were provided for 25...
European Psychiatry
April 1, 2024
K. Sattler, T. Walia, V. Tsang
Introduction Currently, Ketamine is the only safe, effective, and widely used psychedelic-like medicine in Canada. It has demonstrated notably efficacy in providing relief to those experiencing treatment resistant mental health conditions. Pairing Ketamine treatment with psychotherapy, known as Ketamine Assisted Therapy (KAT), has been shown to yield more enduring outcomes. Work by Greenway et...
European Psychiatry
April 1, 2024
E. Bergaoui, R. Lansari, O. Chehaider et al.
IntroductionThe use of cannabis is associated with developing psychotic disorders, especially for those with a pre-existing vulnerability and elevated familial risk for psychosis.ObjectivesTo assess cannabis use during first episode psychosis and its relationship with patients’ clinical symptoms and functioning.MethodsWe assessed 50 patients hospitalized for first episode psychosis using three...
European Psychiatry
April 1, 2024
O. Martin-Santiago, M. Calvo-Valcarcel, P. Martinez.Gimeno et al.
Introduction Epidemiological studies have established a complex relationship between cannabis consumption and a heightened risk of psychotic disorders, including schizophrenia. However, this connection is multifaceted, influenced by genetics, environment, and individual psychology. Surprisingly, despite a surge in emergency room (ER) visits associated with cannabis consumption and psychosis,...
European Psychiatry
April 1, 2024
J. K. Nowocień, N. Szejko
IntroductionRegular practice of mindfulness has proven effectiveness in the treatment of affective disorders (Cash and Whittingham, 2010), increases the level of satisfaction in life (Brown and Ryan, 2003), as well as the level of self-esteem (Rasmussen & Pidgeon, 2010). Using “Mulholland Drive” (2001) by David Lynch as an example, we will prove that transcendental cinema, through the unique...
European Psychiatry
April 1, 2024
P. Castro, J. Maia
IntroductionPsychedelics are substances consumed for recreational use, the majority of these psychoactive substances are illegal and hard to obtain. Therefore, there is a demand for psychedelics legal and easier to access, these types of drugs are called ‘legal highs’. LSA (lysergic acid amide) is one of these new psychoactive substances, this drug is searched because it is known to have an...
European Psychiatry
April 1, 2024
V. Tsang
IntroductionDepression continues to present significant economic burdens to the Canadian healthcare system. Novel therapies, including those that incorporate psychoactive substances such as ketamine, present an opportunity to evaluate both clinical and economic effectiveness against current standards of care, which may be repeatedly proving ineffective in treating depression for some...
European Psychiatry
2024
Eline Haijen, Petra P M Hurks, Kim P. C. Kuypers
10 citations
Abstract Adults with attention-deficit hyperactivity disorder (ADHD) often struggle with emotion regulation (ER), impacting their empathic skills and relationships. ADHD medication might not be as effective for ER issues as for ADHD symptoms. Microdosing (MD) psychedelics has shown promise for ADHD treatment and previous studies reported social-emotional benefits. Two online prospective studies...
European Psychiatry
November 17, 2023
Émeline Gaudré-Wattinne, Lila Mekaoui, Maud Rothärmel et al.
1 citation
Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/2019 the French National Agency for Medicines and Health Product Safety granted an early access program for Esketamine nasal spray framed by a...
European Psychiatry
November 17, 2023
K. Beck, Atheeshaan Arumuham, S. Brugger et al.
1 citation
Introduction N-Methyl-D-Aspartate Receptor (NMDAR) hypofunction is hypothesised to underlie psychosis but this has not been tested early in illness. Objectives Our aim was to determine if NMDAR availability was lower in patients with first episode psychosis compared to healthy controls. Methods To address this, we studied 40 volunteers (21 patients with first episode psychosis and 19 matched...
European Psychiatry
November 17, 2023
N. Veluri, Z. Mansuri
1 citation
Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketamine, an enantiomer of ketamine for TRD. Objectives To determine the effectiveness of ketamine and...
European Psychiatry
November 17, 2023
L. Silva, L. Bravo
1 citation
Introduction Lysergic acid diethylamide (LSD) a semi synthetic hallucinogen, was first synthetized by Albert Hofmann in 1938 and its psychological properties were not discovered until 1943. There was a brief renaissance of its use in psychiatry, specifically in assisted psychotherapy for the treatment of alcoholism, neurosis and psychosomatic disorders. However, research with LSD and others...
European Psychiatry
November 17, 2023
V. Gallese
In spite of the historically consolidated psychopathological perspective, neuroscientific research applied to schizophrenia has so far almost entirely neglected the first-person experiential dimension of this syndrome, mainly focusing on higher-order cognitive functions such as executive function, working memory, theory of mind, and the like. An alternative view posits that schizophrenia is a...